AGP Executive Report
Last update: 5 hours agoChikungunya Vaccine: UK regulators withdrew authorization for Valneva’s IXCHIQ after reviewing existing safety data; the company said no new safety issue prompted the decision. The withdrawal applies only to the UK, with authorizations in the EU, Canada, Brazil and other markets unchanged. Valneva will not appeal.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.